Original Source(s)
Related Content
Surveillance May Reduce CIN 2 Overtreatment
Risk-based management may reduce unnecessary excisions in selected patients with CIN 2.
June 26, 2026
-
3 min
FDA Expands Gene Therapy for Younger Patients
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
July 2, 2026
-
3 min
Narrow DCIS Margins May Not Always Warrant Reexcision
An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.
July 20, 2026
-
6 min
